Fig. 2

Mutational landscape of extracranial tumors and brain metastases. TMB for matched BrM-ECT and FFPE-frozen tumors with somatic variant calls, a paired FFPE BrM and FFPE ECT (n = 6 patients) and b paired FFPE BrM and frozen BrM (n = 15). Note that median lines shown in a and b are for all samples plotted. c TMB by PAM50 inferred intrinsic subtype for each sample type (FFPE BrM, n = 17; FFPE ECT, n = 6; Frozen BrM, n = 19; the two PAM50 Normal samples are not shown nor analyzed). d Circos plot demonstrating the total number of variants in each sample (by the width of the sample’s band in the outer ring) and the number of shared variants among the samples in patients with matched FFPE ECT and FFPE BrM (n = 6; by the width of the central bands). Secondary BrM and ECT samples are not shown nor analyzed in a-d. Oncoplots of e clinically relevant and f top 50 altered genes identified in tumor samples with somatic variant calls, including FFPE BrM (n = 18 patients, m = 19 samples), frozen BrM (n = 19, m = 20), and FFPE ECT (n = 7, m = 8). Top barcharts above e and f show tumor mutational burden (TMB) as the number of non-silent mutations by mutation type called across the genome. Clinical source refers to the location of the lesion assessed for clinical biomarkers (ER, PR and HER2) in that patient’s medical records used to assign the clinical subtype of the BrM